- Inhibitors
- Antibodies
- Compound Libraries
- New Products
- Contact Us
research use only
Cat.No.S2559
| Related Targets | Adrenergic Receptor Estrogen/progestogen Receptor GPR Androgen Receptor ACE RAAS Progesterone Receptor Opioid Receptor PGES THR |
|---|---|
| Other Glucocorticoid Receptor Inhibitors | AL082D06 (20S)-Protopanaxatriol Corticosterone Cortodoxone |
|
In vitro |
DMSO
: 7 mg/mL
(17.39 mM)
Water : Insoluble Ethanol : Insoluble |
|
In vivo |
|||||
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.
| Molecular Weight | 402.48 | Formula | C23H30O6 |
Storage (From the date of receipt) | |
|---|---|---|---|---|---|
| CAS No. | 50-04-4 | Download SDF | Storage of Stock Solutions |
|
|
| Synonyms | Cortone,NSC 49420 | Smiles | CC(=O)OCC(=O)C1(CCC2C1(CC(=O)C3C2CCC4=CC(=O)CCC34C)C)O | ||
| Targets/IC50/Ki |
Glucocorticoid receptor
|
|---|
(data from https://clinicaltrials.gov, updated on 2024-05-22)
| NCT Number | Recruitment | Conditions | Sponsor/Collaborators | Start Date | Phases |
|---|---|---|---|---|---|
| NCT04855630 | Recruiting | Alzheimer Disease|Dementia |
University of Miami|Shipley Foundation|Dreem |
March 1 2023 | Not Applicable |
| NCT05790083 | Active not recruiting | Atopic Dermatitis|Eczema-Prone Skin |
Bionorica SE |
January 3 2023 | Not Applicable |
| NCT05336968 | Recruiting | Osteoarthritis Knee |
United Health Services Hospitals Inc. |
September 15 2022 | Phase 4 |
| NCT05435781 | Recruiting | Adrenal Insufficiency|Polymyalgia Rheumatica|Giant Cell Arteritis |
Ulla Feldt-Rasmussen|Aarhus University Hospital|Odense University Hospital|Rigshospitalet Denmark |
June 7 2022 | Phase 4 |
| NCT05237440 | Recruiting | Obesity |
University Hospital Limoges |
April 13 2022 | Not Applicable |
| NCT05222152 | Active not recruiting | Primary Adrenal Insufficiency |
Diurnal Limited |
November 23 2021 | Phase 2 |
Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.